Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRA: Selumetinib with Adjuvant RAI in Thyroid Cancer
NCT01843062Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Aug 2013
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of selumetinib in differentiated thyroid cancer (DTC), sponsored by AstraZeneca. Started Aug 2013; status: terminated.
02
Drugs
selumetinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT01843062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01843062.